Inhibiting microglia proliferation after spinal cord injury improves recovery in mice and nonhuman primates

Gaëtan Poulen1, Emilie Aloy1, Claire M Bringuier2

  • 1MMDN, Univ. Montpellier, EPHE, INSERM, Montpellier, France; Department of Neurosurgery, CHU, Montpellier, France.

Theranostics
|September 15, 2021
PubMed

Insights

Transient pharmacological reduction of microglia proliferation using GW2580 improved functional recovery and tissue preservation in spinal cord injury (SCI) models. This approach shows promise for treating SCI and other central nervous system disorders.

Area of Science:

  • Neuroscience
  • Regenerative Medicine
  • Pharmacology

Background:

  • Spinal cord injury (SCI) lacks curative treatments, with microglia activation playing a key role in functional recovery.
  • Microglia proliferation is a critical process following SCI, influencing outcomes.

Purpose of the Study:

  • To investigate the therapeutic potential of transiently reducing microglia proliferation post-SCI.
  • To evaluate the effects of GW2580, a colony stimulating factor-1 receptor (CSF1R) inhibitor, on functional recovery and pathology in SCI models.

Main Methods:

  • Oral administration of GW2580, a CSF1R inhibitor, to mice and nonhuman primates following SCI.
  • Assessment of locomotor function, spinal cord pathology, and glial reactivity.
  • Cell-specific transcriptomic analysis to identify molecular changes in microglia.

Main Results:

  • GW2580 treatment improved motor function recovery and promoted tissue preservation in mice.
  • In nonhuman primates, GW2580 reduced microglia proliferation and enhanced motor function recovery.
  • GW2580 modulated glial reactivity and downregulated proliferation-associated and inflammatory genes in microglia.

Conclusions:

  • Transient GW2580 administration represents a promising therapeutic strategy for SCI.
  • This approach may also benefit other central nervous system disorders characterized by microglia activation.

Related Concept Videos